Dental giant Envista names Paul Keel new CEO

Search Dental Tribune

Envista names Paul Keel new CEO

Paul Keel will begin his new roles as CEO and member of the board of directors at Envista on 1 May. (Image: Pickadook/Shutterstock)

Wed. 24 April 2024


BREA, Calif., US: Envista Holdings has appointed Paul Keel as its new CEO and a member of its board of directors, effective from 1 May. The company owns more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. It announced in February that it was seeking a successor to Amir Aghdaei, who will continue to support the transition as a senior adviser.

Keel’s “strong track record as CEO of a public, diversified, global innovation company makes him the right leader for Envista at this stage in our growth journey,” said Scott Huennekens, chairman of Envista, in a press release. “His pertinent combination of accelerating growth and operational excellence with his experience in the medical and oral care markets make him uniquely qualified to lead Envista in our mission to digitise, personalise, and democratise dental care,” Huennekens added.

Keel commented: “It’s a great honour to lead Envista at this exciting time in our deep and rich history. I know and admire the company and industry. I am thrilled to build on Envista’s strong foundation, doing ever more to serve all our stakeholders—our customers, their patients, our colleagues, our communities and our shareholders.”

Keel most recently served as CEO of global technology company Smiths Group. He previously spent 16 years at 3M, where he served in various leadership roles, including group president of the company’s consumer business group, president of 3M Medical and president of 3M’s specialty dental business. Prior to that, he held positions of responsibility at General Electric, McKinsey & Company and General Mills. Paul holds a BA from Carleton College and an MBA from Harvard Business School, both in the US.

To post a reply please login or register